Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) Director Paul A. Friedman sold 18,710 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $242.96, for a total transaction of $4,545,781.60. Following the sale, the director now owns 185,735 shares of the company's stock, valued at $45,126,175.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Madrigal Pharmaceuticals Stock Performance
Madrigal Pharmaceuticals stock opened at $243.04 on Friday. Madrigal Pharmaceuticals, Inc. has a 52-week low of $119.76 and a 52-week high of $322.67. The company has a fifty day simple moving average of $239.37 and a 200-day simple moving average of $204.26. The company has a quick ratio of 5.38, a current ratio of 5.38 and a debt-to-equity ratio of 0.28.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($5.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.26) by ($0.42). During the same period last year, the firm earned ($4.98) EPS. As a group, sell-side analysts predict that Madrigal Pharmaceuticals, Inc. will post -21.48 EPS for the current year.
Analyst Upgrades and Downgrades
The #1 Biotech Stock to Have on Your Radar in 2024…
From Huge Alerts | Ad
Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!
Learn more about why Zack’s has a BULLISH nearly $19 price target on BSEM right now!
MDGL has been the subject of several analyst reports. StockNews.com upgraded shares of Madrigal Pharmaceuticals to a "sell" rating in a research note on Thursday, March 28th. Citigroup boosted their target price on shares of Madrigal Pharmaceuticals from $382.00 to $389.00 and gave the company a "buy" rating in a research note on Friday, March 15th. HC Wainwright boosted their price target on shares of Madrigal Pharmaceuticals from $405.00 to $425.00 and gave the stock a "buy" rating in a report on Friday, March 15th. JMP Securities boosted their price target on shares of Madrigal Pharmaceuticals from $351.00 to $397.00 and gave the stock an "outperform" rating in a report on Friday, March 15th. Finally, UBS Group boosted their price target on shares of Madrigal Pharmaceuticals from $337.00 to $410.00 and gave the stock a "buy" rating in a report on Friday, March 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Madrigal Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $377.40.
View Our Latest Analysis on MDGL
Institutional Investors Weigh In On Madrigal Pharmaceuticals
Hedge funds have recently modified their holdings of the company. Montag A & Associates Inc. lifted its position in Madrigal Pharmaceuticals by 223.3% in the third quarter. Montag A & Associates Inc. now owns 194 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 134 shares during the last quarter. Global Retirement Partners LLC lifted its position in Madrigal Pharmaceuticals by 454.5% in the fourth quarter. Global Retirement Partners LLC now owns 122 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 100 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Madrigal Pharmaceuticals in the first quarter valued at about $55,000. KBC Group NV acquired a new position in Madrigal Pharmaceuticals in the fourth quarter valued at about $60,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Madrigal Pharmaceuticals by 95.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 468 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 228 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.
About Madrigal Pharmaceuticals
(
Get Free Report)
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
